Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 4 | 1 |
List of Figures | 5 | 1 |
Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 | 5 | 2 |
Amarantus Bioscience Holdings, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 | 7 | 1 |
Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 | 8 | 1 |
Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 | 9 | 1 |
Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 | 10 | 1 |
Amarantus Bioscience Holdings, Inc., Medical Equipment, Deal Details | 11 | 14 |
Asset Purchase | 11 | 1 |
Amarantus Bioscience Acquires Rights To LymPro Test From Memory Dx | 11 | 2 |
Amarantus BioScience Acquires Intellectual Property Portfolio From Power3 Medical Products | 13 | 2 |
Venture Financing | 15 | 1 |
Cerora Raises Additional Funds through Second Closing of Seed Financing | 15 | 1 |
Partnerships | 16 | 1 |
Amarantus BioSciences Exercises Option For Licensing Agreement With Memory Dx For Alzheimer's Diagnostic Blood Test | 16 | 2 |
Amarantus BioSciences Enters Into Licensing Agreement With Power3 Medical Products | 18 | 2 |
Generex Biotech Enters Into Licensing Agreement With Amarantus BioSciences | 20 | 2 |
Equity Offering | 22 | 1 |
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock | 22 | 1 |
Acquisition | 23 | 1 |
Avant Diagnostics Acquires Amarantus Diagnostics | 23 | 1 |
Amarantus BioScience Acquires DioGenix | 24 | 1 |
Amarantus Bioscience Holdings, Inc. - Key Competitors | 25 | 1 |
Key Employees | 26 | 1 |
Locations And Subsidiaries | 27 | 1 |
Head Office | 27 | 1 |
Other Locations &Subsidiaries | 27 | 1 |
Recent Developments | 28 | 1 |
Financial Announcements | 28 | 1 |
Jun 03, 2016: Amarantus Announces Fiscal Year 2015 and First Quarter 2016 Financial Results | 28 | 2 |
Aug 17, 2015: Amarantus Reports Second Quarter 2015 Financial Results and Business Overview | 30 | 3 |
May 20, 2015: Amarantus Reports First Quarter 2015 Financial Results and Business Overview | 33 | 2 |
Apr 07, 2015: Amarantus Reports 2014 Financial Results and Business Overview | 35 | 3 |
Corporate Communications | 38 | 1 |
Jul 27, 2015: Amarantus Diagnostics Establishes Strategic Advisory Committee | 38 | 2 |
Jul 13, 2015: Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS | 40 | 1 |
Jan 22, 2015: Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board | 41 | 2 |
Product News | 43 | 1 |
Aug 06, 2015: Researchers Funded by the National MS Society Build on Commercial Partnership to Develop Diagnostic Test for MS | 43 | 1 |
May 11, 2015: Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise Diagnostic for Multiple Sclerosis | 44 | 1 |
Mar 23, 2015: Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015 | 45 | 1 |
Feb 18, 2015: Amarantus Announces First Alzheimer s Biomarker Services Collaboration for LymPro Test with Anavex Life Sciences | 46 | 2 |
Jan 15, 2015: Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test Confirming Statistically Significant Markers for Alzheimer's | 48 | 1 |
Clinical Trials | 49 | 1 |
May 11, 2015: Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise Diagnostic for Multiple Sclerosis | 49 | 1 |
Jan 15, 2015: Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test Confirming Statistically Significant Markers for Alzheimer's | 50 | 1 |
Other Significant Developments | 51 | 1 |
Feb 22, 2016: Amarantus and Lonza Walkersville Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute Program | 51 | 1 |
7 Feb 18, 2015: Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test With Anavex Life Sciences | 51 | 2 |
Appendix | 53 | 1 |
Methodology | 53 | 1 |
About GlobalData | 53 | 1 |
Contact Us | 53 | 1 |
Disclaimer | 53 | 1 |